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Recently, nerve growth factor (NGF) inhibitors have been introduced for treatment of osteoarthritis
(OA) symptoms, and have shown good analgesic efﬁcacy and improvement in function in patients
with OA. However, anti- (a-)NGF trials in OA had been suspended by the U.S. Food and
Drug Administration (FDA) due to concerns over accelerated rates of OA progression and osteonec-
rosis. Since a-NGF therapies offer potential as the ﬁrst new class of analgesics for many years, future
studies assessing a-NGF compounds will have to follow stringent eligibility criteria and will require a
rigorous safety monitoring. Imaging is paramount to identify potential negative outcomes as early as
possible. These imaging ﬁndings include atrophic OA, osteonecrosis and others at eligibility and
especially rapid progressive OA (RPOA) during the course of treatment. This second part of the a-NGF
imaging atlas will present speciﬁc hip joint imaging ﬁndings that are relevant for eligibility and safety
and represent potential adverse joint events on radiography and magnetic resonance imaging (MRI) in
studies investigating a-NGF compounds. Researchers and clinicians should become familiar with
several of these entities, and especially osteonecrosis of the hip and insufﬁciency fractures are rela-
tively common ﬁndings in such a patientpopulation. As several of these diagnoses may only be
detected at late stages using radiographic methods, MRI plays an important role in identifying such
pathologies early and at potentially still reversible stages before irreversible joint destruction has
occurred.
© 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
b-nerve growth factor (NGF), a protein ﬁrst identiﬁed in the
central nervous system, acts as a major mediator in chronic pain
in many disease entities1. b-NGF has been identiﬁed in the: F.W. Roemer, Department
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lf of Osteoarthritis Research Societsynovial membrane and synovial ﬂuid of joints affected by
rheumatoid arthritis and osteoarthritis (OA)2,3. b-NGF can be
antagonized using humanized monoclonal antibodies directed
either against b-NGF or it's receptor4. Recently, NGF inhibitors
have been introduced for treatment of OA symptoms, and have
shown good analgesic efﬁcacy and improvement in function in
patients with OA5,6 However, anti- (a-)NGF trials in OA had been
suspended by the U.S. Food and Drug Administration (FDA) due
to concerns over accelerated rates of OA progression and osteo-
necrosis leading to total joint replacement especially in patients
treated simultaneously with a-NGF and non-steroidal anti-in-
ﬂammatory drugs (NSAIDS)7. In March 2012 the Arthritis Advi-
sory Committee to the FDA unanimously recommended that
there is a role for the ongoing development of NGF inhibitors and
a-NGF programs are suspected to resume in the near future8.y International.
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analgesics for many years, future studies assessing a-NGF com-
pounds will have to follow stringent eligibility criteria and will
require rigorous safety monitoring. While disease-modifying ef-
fects are not expected in a-NGF treatment, imaging is paramount
to identify potential negative outcomes as early as possible.
These imaging ﬁndings include atrophic OA, osteonecrosis and
others at eligibility and especially rapid progressive OA (RPOA)
Type I (i.e., rapid progression of JSN >1 mm/year or other
program-speciﬁc cut-off) and RPOA II (i.e., abnormal loss of bone
or bone destruction that does not normally occur in end-stage
OA) during the course of treatment9. Imaging ﬁndings for pa-
tients entering or enrolled in a-NGF trials concerning knee joint
speciﬁc diagnoses have been laid out in detail in the previous
chapter. This second part of the a-NGF imaging atlas will present
speciﬁc hip joint imaging ﬁndings that are relevant for eligibility
and safety and represent potential adverse joint events on radi-
ography and magnetic resonance imaging (MRI) in studies
investigating a-NGF compounds. Researchers and clinicians
should become familiar with several of these entities, and
especially osteonecrosis of the hip and insufﬁciency fractures are
relatively common ﬁndings in such a patient-population10. As
several of these diagnoses may only be detected at late stages
using radiographic methods, MRI plays an important role in
identifying such pathologies early and at potentially still
reversible stages before irreversible joint destruction has
occurred11,12. The aim of this atlas section focusing on the hip
joint is to present typical ﬁndings relevant for study design and
during the course of a study, and to inform potential expert
readers about terminology and promote agreement on speciﬁc
diagnoses and imaging ﬁndings.
Methods
Development of this part of the atlas was based on eight in-
person and 20þ teleconference meetings of four experienced
musculoskeletal radiologists (FWR, CH, KH, AG) and a senior
imaging expert (CGM) representing a contract research organi-
zation (CRO) active in a-NGF studies to deﬁne potential eligibility
and safety ﬁndings relevant for a-NGF clinical trials. For the hip
section of the atlas 450þ baseline and follow-up radiographic
and MRI image examples of hip joints were reviewed in
consensus to deﬁne the most relevant and characteristic imaging
ﬁndings of entities that may be encountered during a-NGF
studies at screening or during the course of a study. Images for
this atlas were derived from personal teaching and training ﬁles
of these radiologists and partly from a Pﬁzer library of hip ra-
diographs obtained during the course of the tanezumab program.
The same terminology deﬁnitions that have been introduced in
the knee section of this atlas will be used for the hip section
including the major adverse events deﬁned as RPOA types I
and II.
Osteonecrosis of the hip is a relatively common ﬁnding that
may lead to articular collapse. While the etiology is not
always unequivocal, i.e., vascular infarcts vs subchondral insuf-
ﬁciency fracture, consensus exists that concomitant bone
marrow edema-like signal changes in the femoral head and neck
visible on MRI are responsible for manifestations of pain13. It has
to be noted that not all edema-like changes represent early
stages of osteonecrosis and that not all forms of osteonecrosis are
associated with a relevant amount of surrounding edema.Beginning deformity of the femoral head is always a sign of
articular surface collapse and an indication of irreversible joint
destruction14. Classiﬁcations such as Steinberg, Ficat or Associa-
tion Research Circulation Osseous (ARCO) are not applied in a
uniform manner but agree on the fact that early stages cannot be
visualized by radiography and that transformation to later, irre-
versible stages is characterized by deformity of the femoral head
and articular fractures indicating surface collapse15e17. We will
use the ARCO classiﬁcation for illustrations of some of the im-
aging ﬁndings.
The radiographic imaging acquisition protocol that is being
recommended for the hip in aNGF studies for eligbility and safety
assessment is a bilateral anterior-posterior view of the pelvis and a
frog lateral view of each hip separately18. The MRI protocol should
be at least an abbreviated standard clinical protocol with both hips
visualized simultaneously for comparative reasons consisting of at
least a coronal T1-weighted non fat suppressed sequence, a coronal
STIR (or T2-weighted fat suppressed) sequence, and an axial proton
density-weighted fat suppressed sequence. The use of 1.5 T or 3 T
large boreMRI is recommended for assessment of the hips in a-NGF
studies.Results
Figure 1 represents two examples of RPOA type I leading to
complete loss of joint space over periods of less than 1 year.
RPOA type II is characterized by bone loss and destruction of at
least one articular surface that is unusual for common manifes-
tations of OA and is visualized in Fig. 2. Atrophic OA is a disease-
phenotype characterized by marked loss of joint space without
substantial concomitant osteophyte formation and is exempliﬁed
in the example images in Fig. 3. This entity is thought to be prone
to more rapid progression compared to common osteophyte-
dominated OA. Figure 4 shows typical examples of insufﬁciency
fractures of the femoral neck, a common ﬁnding in elderly
osteoporotic patients that has to be expected also in a-NGF
studies. Such insufﬁciency fractures are commonly associated
with large areas of bone marrow edema. Figure 5 illustrates X-ray
ﬁndings of early osteonecrosis and the progression to irreversible
stages characterized on X-ray by deformity and asphericity of the
femoral head. Figure 6 expands on the differences between
osteonecrosis and subchondral insufﬁciency fractures (SIF), and
the relevance of bone marrow edema to explain joint pain.
Radiographic signs of more advanced stages of osteonecrosis are
presented in Fig. 7 including the so-called crescent sign repre-
senting a subchondral fracture. Figure 8 represents advanced
osteonecrosis with articular collapse and a case of fast progres-
sion. Examples of idiopathic bone marrow edema syndrome are
shown in Figs. 9 and 10 that represent painful conditions with a
potentially good prognosis. These may be radiographically occult
or be characterized by focal osteopenia. Other arthropathies may
or may not be diagnoses of potential exclusion at eligibility and
are presented in Figs. 11e13. While ﬁndings of malignancy or
inﬂammatory arthritis will always be diagnoses of exclusion at
eligibility or safety, other incidental imaging ﬁndings such as
bone islands, herniation pits or small entheseal calciﬁcations
may not. The speciﬁc study protocols have to lay out, which of
these benign ﬁndings are relevant for a given study. Commonly
these may be considered a safety ﬁnding if they potentially in-
crease the risk of fracture.
Fig. 1. RPOA Type I. A. Baseline anterioreposterior (a.p.) image shows equivocal superior-lateral joint space narrowing (JSN e arrows) and no relevant osteophytes. B. Follow-up
image 8 months later depicts complete loss of joint space superior-medially and laterally (arrows). At follow-up still no osteophyte formation is observed. C. Another case exhibits
marked superior-medial JSN but not lateral, consistent with radiographic hip OA Kellgren-Lawrence grade III (arrows). B. Follow-up image 10 months later illustrates increase in JSN
superior-medially and in addition incident complete loss of joint space superior-laterally (arrows).
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Fig. 2. RPOA Type II. A. Baseline anteroposterior radiograph shows marked superior-medial JSN (black arrows). In addition, note deformity of the acetabular fossa (white arrows). B.
Follow-up image 12 months later visualizes complete obliteration of joint space, deformity and partial destruction of the femoral head (arrows). In addition there is deformity of the
acetabular fossa. C. Another hip joint shows superior JSN (arrows) without relevant osteophytes present. D. Follow up image 12 months later shows near-complete destruction of the
femoral head (arrows) and subsequent migration of the femur superiorly. Findings are consistent with RPOA Type II.
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Fig. 3. Atrophic OA. Osteoarthritic joints with marked JSN but only little or no osteophyte formation may be considered as exhibiting an atrophic OA phenotype. These joints are
potentially at increased risk for more rapid progression or destruction. A. Example shows normal joint space in the left hip but deﬁnite narrowing on the right (arrows). No
osteophytes are present. B. Complete loss of joint space is depicted in this example (arrows). No acetabular and only a small lateral femoral osteophyte are observed. C. Another case
of atrophic OA shows complete obliteration of the hip joint space without any osteophytes.
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Fig. 4. Insufﬁciency fractures are a diagnosis of exclusion at eligibility in a-NGF studies. A. Radiograph shows typical sclerotic band (arrows) at the medial femoral neck representing
a subacute insufﬁciency fracture in typical location. B. Corresponding proton density-weighted fat suppressed MRI shows fracture line (arrows) and marked surrounding bone
marrow edema (asterisk). C. The corresponding T1-weighted image superiorly depicts the fracture line (arrows). D. Another typical case of a femoral neck insufﬁciency fracture
(arrow) is depicted on this coronal T2-weighted fat suppressed MR image. Note difuse surrounding bone marrow edema (asterisk). Insufﬁciency fractures may be radiographically
occult and may be a reason for discrepancy between unremarkable radiographic ﬁndings and symptoms.
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Fig. 5. Avsacular osteonecrosis of the hip is commonly graded according to the ARCO classiﬁcation. Early signs of ON may be radiographiccally occult, later stages are characterized
by articular collapse. A. Osteonecrosis ARCO grade II with circumscribed osteopenia demarcated by a sclerotic rim (arrows). Femoral sphericity is preserved. B. Another example of
osteonecrosis ARCO grade II with circumscribed radiolucency but only discrete sclerotic demarcation (arrows). Articular surface contour is intact. C. Osteonecrosis ARCO grade III
Early signs of articular collapse include discrete asphericity of the femoral head contour (large arrows). In addition focal osteopenia is observed (small arrows). D. Another example
shows discrete cortical depression (arrow) at the lateral demarcation of a subchondral osteonecrotic area representing ARCO grade III.
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Fig. 6. Early stages of osteonecrosis of the hip may only be detectable by MRI. A. On the right side coronal T1-weighted MRI shows characteristic hypointense band (arrow)
demarcating an area of osteonecrosis representing stage II according to ARCO. No accompanying edema is encountered, femoral head contour is intact. Left femoral head shows
diffuse hypointensity representing bone marrow edema (asterisk). B. Corresponding T2-weighted fat suppressed image shows so-called double line sign on the right side (small
white arrows). A small focal area of subchondral hypointensity on the left is consistent with an area of osteonecrosis (small black arrow). In addition there is marked bone marrow
edema (asterisk). Note concomitant reactive edema also in the acetabulum on the left (large white arrow). C. Another case depicts a subchondral insufﬁciency fracture (arrow) with
extensive surrounding bone marrow edema as seen in this coronal T1-weighted MR image. D. Corresponding proton density-weighted fat suppressed MR image shows full extent of
edema (arrows). This is a potentially reversible ﬁnding with the possibility of complete resolution.
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Fig. 7. Advanced osteonecrosis. A. The crescent sign represents a subarticular fracture and beginning collapse of femoral head. It is visualized as a radiolucent line parallel to the
articular surface (arrows). B. Coronal T2-weighted fat suppressed MR image in another patient shows crescent sign on MRI (arrows) representing ﬂuid between the articular surface
and the subchondral bone and thus, delamination and incipient collapse. Note concomitant marked inﬂammatory joint response reﬂected as a large effusion and synovitic reaction
(asterisk). C. Coronal T1-weighted image shows articular deformity at the lateral border of osteonecrosis consistent with ARCO grade III. D. Another case of ARCO grade III
osteonecrosis shows the crescent sign on X-ray (small arrows) and beginning articular surface collapse (large arrow).
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Fig. 8. Advanced osteonecrosis. A. Radiograph shows deformity of the femoral head and marked asphericity unusual for common OA. Complete obliteration of joint space (black
arrows) and subchondral cystic lesions (white arrows) are observed. While no deﬁnite osteonecrotic fragment is seen in this image previous exams had clearly depicted osteo-
necrotic area that has been obliterated by the femoral head collapse. B. Corresponding proton-density-weighted fat suppressed coronal MR image shows diffuse hyperintense bone
marrow edema in the femoral head and neck (white asterisk) but also in the acetabulum (black asterisk) explaining persistent severe pain in this patient. C. Beginning collapse and
deformation of femoral head (large arrow) is seen in this example of advanced osteonecrosis. Note fracture line, which is demarcating the area of necrosis (small arrows). D. Follow-
up image 6 months later shows increasing collapse and depression of necrotic fragment into the femoral head (small arrows). Fracture line indicates complete dissecation of
fragment from femoral head (large arrows).
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Fig. 9. Large areas of bone marrow edema may explain pain and are not obvious on conventional radiography. A. This example of an a.p. pelvic radiograph shows diffuse
radiolucency in the left femoral head suggesting osteopenia (arrows). No articular abnormalities are observed. B. Corresponding T1-weighted MRI depicts an extensive area of
hypointense bone marrow edema in the femoral head and neck (arrows) without presence of a fracture line. C. Coronal T2-weighted fat suppressed MR image conﬁrms bone
marrow edema-like signal (asterisk) extending far into the metaphyseal femur. A diagnosis of transient bone marrow edema syndrome was established based on imaging ﬁndings
and history of absence of trauma.
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Fig. 10. SIF. A. The anteroposterior radiograph appears normal in this patient with incident severe hip pain. B. Corresponding coronal contrast-enhanced T1-weighted fat sup-
pressed MR image shows a diffuse area of bone marrow edema in the femoral head and neck (asterisk). In addition, there is a small focus of osteonecrosis located directly sub-
chondrally (large arrow) and a discrete subchondral fracture line (small arrow). C. Another case of incident hip pain. Radiograph shows slight osteopenia especially in the lateral
aspect of femoral head. No fracture or signs of osteonecrosis are seen. D. Corresponding coronal T2 weighted fat suppressed MR image shows extensive bone marrow edema in the
femoral head and neck and a discrete fracture line subchondrally (arrow). Without evidence of SIF, both cases would be diagnosed as idiopathic bone marrow edema syndrome,
which is a painful condition of unknown cause that is also called transient osteoporosis. Characteristic is a discrepancy between clinical ﬁndings, i.e., severe pain, and radiographic
ﬁndings. As idiopathic bone marrow edema syndrome may increase risk of fracture, this may be a ﬁnding of exclusion at eligibility or on-study.
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Fig. 11. Other conditions. A. Pelvic radiograph shows exuberant femoral (small arrows) and acetabular (large arrows) osteophyte formation on both sides and multiple periartcular
calciﬁcations. There is marked JSN on the right. Finding is consistent with diffuse idiopathic hyperostosis (DISH) presenting as hypertrophic OA. This is a ﬁnding that may be
encountered at eligibility, but is commonly not considered a diagnosis of exclusion. B. Another example of hypertrophic, but isolated acetabular osteophyte formation (arrows). Note
in addition calciﬁc traction enthesopathy at the lesser trochanter and also calciﬁcation of the sacro-tuberous ligament (small arrows). These calciﬁcations represent incidental
ﬁnding and are not exclusive at eligibility. C. Small entheseal calciﬁcations as shown in this case at the hamstring attachment of the ischiac tuberosity (large white arrow) are
common and not a diagnosis of exclusion. In addition there is JSN (black arrows) and acetabular lipping (small white arrow).
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Fig. 12. Other conditions. A. A large lytic lesion is seen in the femoral neck region extending to the femoral head (arrows). Finding is consistent with a malignant osteolysis, in this
case a conﬁrmed metastasis from breast cancer. Any imaging ﬁndings suggesting malignancy at eligibility are diagnoses of exclusion. B. Severe concentric JSN is seen in this case. In
addition there are multiple subchondral cystic lesions (arrows) not typical for common OA. These lesions represent rheumatic inﬂammatory erosions in a patient with rheumatoid
arthritis. C. Sclerotic radiolucent lesion in the lateral femoral neck region that is typical for a benign herniation pit (also known as Pitt's pit) representing intraosseous ﬁbrocystic
lesions usually associated with femoro-actebaular impingement. D. Well-demarcated radio-dense lesion in the trochanteric region representing a benign bone island (also termed
“enostosis”). Herniation pits and bone islands are common ﬁndings without pathologic relevance and do not represent diagnoses of exclusion.
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Fig. 13. Other conditions. A. Incident hip pain for 2 weeks. Radiograph shows diffuse loss of joint space (arrows) without osteophyte formation. B. Corresponding T2-weighted fat
suppressed MR image depicts extensive areas of femoral and acetabular bone marrow edema (arrows) and marked effusion and synovitis (asterisks). Finding is consistent with
acute septic arthritis. C. Coronal T2-weighted fat suppressed MRI shows a large hypointense lesion of the femoral neck and intertrochanteric region (arrows). The lesion is sur-
rounded by hyperintense bone marrow edema. D. On the T1-weighted MR image the lesion is depicted in hypointense fashion (long arrows) and in addition there is a pathologic
fracture of the femoral head (short arrow) that was not seen on the radiograph (not shown). Finding represents a metastasis from prostate cancer with secondary fracture.
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